GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Cyclically Adjusted FCF per Share

Predictive Oncology (FRA:S1K) Cyclically Adjusted FCF per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted FCF per Share?

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Predictive Oncology's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.780. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 23.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 16.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Predictive Oncology was 23.70% per year. The lowest was 8.30% per year. And the median was 12.30% per year.

As of today (2024-06-25), Predictive Oncology's current stock price is €4.00. Predictive Oncology's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.00. Predictive Oncology's Cyclically Adjusted Price-to-FCF of today is .


Predictive Oncology Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted FCF per Share Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,437.72 -2,562.28 -2,911.21 -2,488.54 -

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,693.71 -1,448.20 -2,019.55 - -

Competitive Comparison of Predictive Oncology's Cyclically Adjusted FCF per Share

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted Price-to-FCF falls into.



Predictive Oncology Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Predictive Oncology's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.78/131.7762*131.7762
=-0.780

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -145.000 100.560 -190.012
201409 -954.000 100.428 -1,251.790
201412 -185.000 99.070 -246.075
201503 -12.000 99.621 -15.873
201506 -186.000 100.684 -243.439
201509 -3,955.000 100.392 -5,191.424
201512 -2,650.000 99.792 -3,499.334
201603 -360.750 100.470 -473.157
201606 -82.231 101.688 -106.562
201609 -48.765 101.861 -63.087
201612 -28.348 101.863 -36.673
201703 -34.563 102.862 -44.278
201706 -26.645 103.349 -33.974
201709 -29.161 104.136 -36.901
201712 -33.939 104.011 -42.999
201803 -24.912 105.290 -31.179
201806 -21.966 106.317 -27.226
201809 -13.258 106.507 -16.404
201812 -14.662 105.998 -18.228
201903 -22.987 107.251 -28.244
201906 -5.903 108.070 -7.198
201909 -10.994 108.329 -13.374
201912 -13.492 108.420 -16.398
202003 -11.198 108.902 -13.550
202006 -6.785 108.767 -8.220
202009 -3.786 109.815 -4.543
202012 -2.080 109.897 -2.494
202103 -1.709 111.754 -2.015
202106 -0.787 114.631 -0.905
202109 -0.798 115.734 -0.909
202112 -1.062 117.630 -1.190
202203 -0.875 121.301 -0.951
202206 -0.928 125.017 -0.978
202209 -0.735 125.227 -0.773
202212 -0.821 125.222 -0.864
202303 -0.818 127.348 -0.846
202306 -0.885 128.729 -0.906
202309 -0.723 129.860 -0.734
202312 -0.699 129.419 -0.712
202403 -0.780 131.776 -0.780

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Predictive Oncology  (FRA:S1K) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Predictive Oncology Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (FRA:S1K) Business Description

Traded in Other Exchanges
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines